Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia

Jessica C. Pahler, Stacey Ruiz, Irina Niemer, Leslie R. Calvert, Michael Andreeff, Michael Keating, Stefan Faderl, David McConkey

Research output: Contribution to journalArticle

Abstract

Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL). Experimental Design: We exposed isolated CLL lymphocytes from >100 patients to various concentrations of bortezomib or other proapoptotic stimuli, and measured DNA fragmentation by propidium iodide staining and flow cytometry. We characterized the effects of bortezomib on release of apoptosis-associated mitochondrial factors and measured downstream effects on caspase activation using a fluorogenic substrate cleavage assay. We assessed potential effects of the drug on inhibitor of apoptosis protein family apoptosis inhibitors by immunoblotting. Finally, we quantified the effects of bortezomib on apoptosis in 5 patients on a Phase II clinical trial. Results: Bortezomib stimulated apoptosis more rapidly than positive controls (glucocorticoid and fludarabine), although substantial heterogeneity was noted with respect to the concentration of drug required to induce cell death. Bortezomib-induced apoptosis was associated with release of SMAC, apoptosis-inducing factor, and cytochrome c from mitochondria, but the drug did not affect levels of inhibitor of apoptosis protein family cell death inhibitors. Levels of apoptosis were marginally elevated in CLL cells obtained from 2 of 5 fludarabine-refractory patients treated with bortezomib in vivo. Conclusion: Our data confirm that bortezomib, like other proteasome inhibitors, has proapoptotic activity in CLL cells.

Original languageEnglish (US)
Pages (from-to)4570-4577
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number12
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Proteasome Inhibitors
B-Cell Chronic Lymphocytic Leukemia
Lymphocytes
Apoptosis
Inhibitor of Apoptosis Proteins
Phase II Clinical Trials
Cell Death
Pharmaceutical Preparations
Boronic Acids
Apoptosis Inducing Factor
Bortezomib
Phase III Clinical Trials
Propidium
DNA Fragmentation
Caspases
Cytochromes c
Fluorescent Dyes
Immunoblotting
Glucocorticoids
Flow Cytometry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. / Pahler, Jessica C.; Ruiz, Stacey; Niemer, Irina; Calvert, Leslie R.; Andreeff, Michael; Keating, Michael; Faderl, Stefan; McConkey, David.

In: Clinical Cancer Research, Vol. 9, No. 12, 01.10.2003, p. 4570-4577.

Research output: Contribution to journalArticle

Pahler, JC, Ruiz, S, Niemer, I, Calvert, LR, Andreeff, M, Keating, M, Faderl, S & McConkey, D 2003, 'Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia', Clinical Cancer Research, vol. 9, no. 12, pp. 4570-4577.
Pahler, Jessica C. ; Ruiz, Stacey ; Niemer, Irina ; Calvert, Leslie R. ; Andreeff, Michael ; Keating, Michael ; Faderl, Stefan ; McConkey, David. / Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 12. pp. 4570-4577.
@article{9e8c95dea878425a9f607e094312e474,
title = "Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia",
abstract = "Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL). Experimental Design: We exposed isolated CLL lymphocytes from >100 patients to various concentrations of bortezomib or other proapoptotic stimuli, and measured DNA fragmentation by propidium iodide staining and flow cytometry. We characterized the effects of bortezomib on release of apoptosis-associated mitochondrial factors and measured downstream effects on caspase activation using a fluorogenic substrate cleavage assay. We assessed potential effects of the drug on inhibitor of apoptosis protein family apoptosis inhibitors by immunoblotting. Finally, we quantified the effects of bortezomib on apoptosis in 5 patients on a Phase II clinical trial. Results: Bortezomib stimulated apoptosis more rapidly than positive controls (glucocorticoid and fludarabine), although substantial heterogeneity was noted with respect to the concentration of drug required to induce cell death. Bortezomib-induced apoptosis was associated with release of SMAC, apoptosis-inducing factor, and cytochrome c from mitochondria, but the drug did not affect levels of inhibitor of apoptosis protein family cell death inhibitors. Levels of apoptosis were marginally elevated in CLL cells obtained from 2 of 5 fludarabine-refractory patients treated with bortezomib in vivo. Conclusion: Our data confirm that bortezomib, like other proteasome inhibitors, has proapoptotic activity in CLL cells.",
author = "Pahler, {Jessica C.} and Stacey Ruiz and Irina Niemer and Calvert, {Leslie R.} and Michael Andreeff and Michael Keating and Stefan Faderl and David McConkey",
year = "2003",
month = "10",
day = "1",
language = "English (US)",
volume = "9",
pages = "4570--4577",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia

AU - Pahler, Jessica C.

AU - Ruiz, Stacey

AU - Niemer, Irina

AU - Calvert, Leslie R.

AU - Andreeff, Michael

AU - Keating, Michael

AU - Faderl, Stefan

AU - McConkey, David

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL). Experimental Design: We exposed isolated CLL lymphocytes from >100 patients to various concentrations of bortezomib or other proapoptotic stimuli, and measured DNA fragmentation by propidium iodide staining and flow cytometry. We characterized the effects of bortezomib on release of apoptosis-associated mitochondrial factors and measured downstream effects on caspase activation using a fluorogenic substrate cleavage assay. We assessed potential effects of the drug on inhibitor of apoptosis protein family apoptosis inhibitors by immunoblotting. Finally, we quantified the effects of bortezomib on apoptosis in 5 patients on a Phase II clinical trial. Results: Bortezomib stimulated apoptosis more rapidly than positive controls (glucocorticoid and fludarabine), although substantial heterogeneity was noted with respect to the concentration of drug required to induce cell death. Bortezomib-induced apoptosis was associated with release of SMAC, apoptosis-inducing factor, and cytochrome c from mitochondria, but the drug did not affect levels of inhibitor of apoptosis protein family cell death inhibitors. Levels of apoptosis were marginally elevated in CLL cells obtained from 2 of 5 fludarabine-refractory patients treated with bortezomib in vivo. Conclusion: Our data confirm that bortezomib, like other proteasome inhibitors, has proapoptotic activity in CLL cells.

AB - Purpose: Bortezomib is a peptide boronic acid inhibitor of the proteasome developed for cancer therapy. The compound is being evaluated currently in Phase II and III clinical trials. Here we characterized the effects and mechanisms of action of bortezomib in cells obtained from patients with chronic lymphocytic leukemia (CLL). Experimental Design: We exposed isolated CLL lymphocytes from >100 patients to various concentrations of bortezomib or other proapoptotic stimuli, and measured DNA fragmentation by propidium iodide staining and flow cytometry. We characterized the effects of bortezomib on release of apoptosis-associated mitochondrial factors and measured downstream effects on caspase activation using a fluorogenic substrate cleavage assay. We assessed potential effects of the drug on inhibitor of apoptosis protein family apoptosis inhibitors by immunoblotting. Finally, we quantified the effects of bortezomib on apoptosis in 5 patients on a Phase II clinical trial. Results: Bortezomib stimulated apoptosis more rapidly than positive controls (glucocorticoid and fludarabine), although substantial heterogeneity was noted with respect to the concentration of drug required to induce cell death. Bortezomib-induced apoptosis was associated with release of SMAC, apoptosis-inducing factor, and cytochrome c from mitochondria, but the drug did not affect levels of inhibitor of apoptosis protein family cell death inhibitors. Levels of apoptosis were marginally elevated in CLL cells obtained from 2 of 5 fludarabine-refractory patients treated with bortezomib in vivo. Conclusion: Our data confirm that bortezomib, like other proteasome inhibitors, has proapoptotic activity in CLL cells.

UR - http://www.scopus.com/inward/record.url?scp=0141960411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141960411&partnerID=8YFLogxK

M3 - Article

C2 - 14555532

AN - SCOPUS:0141960411

VL - 9

SP - 4570

EP - 4577

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -